Cytori Therapeutics probably ranks somewhere near the top of any list of the world's most innovative medical technology companies--or at least a list of its boldest. As CEO Christopher J. Calhoun explains, the company aims to do nothing less than revolutionize health care by leading the way into an era of regenerative medicine, in which damage from cancer, heart disease, and a host of other ailments can be healed with the body's own cells.
The process relies on naturally occurring regenerative cells. "What we have done," Calhoun says, "is developed products that allow a doctor to take a small amount of fat, the same volume as about half a can of Coke, and separate out these healing cells in about one hour." So far, Cytori's technologies have treated more than 3,000 patients for ailments as diverse as heart attack, heart failure, breast tissue reconstruction after cancer surgery, incontinence, and wounds after radiation exposure. Here, Calhoun discusses medical tourism, the challenges of being an entrepreneur, and why he thinks cell therapy could do for medicine what the silicon computer chip did for technology.
What do you say when people ask, "What do you do?"
We restore people's lives using stem cells and other regenerative cells. These cells come from the patients themselves, so we are not destroying embryos or using cells donated by someone else. It turns out that the fat tissue we carry around is the richest source of stem and regenerative cells in the body.
What new idea or innovation is having the most significant impact on medicine?
We are at the beginning of a new age in medicine called Regenerative Medicine. The foundation of this is the living cell, although the emerging field will encompass a broad array of technologies. Remember the early days of the Computer Age circa 1978 where there were these new potentially powerful tools, but not a lot of software or applications? Today, almost everything we use or touch is in some way an offspring of this technology. Regenerative Medicine will explode in a similar way with new tools and applications and treatments, many of which are rapidly being developed around the world and I expect will ultimately impact the lives of billions of people. I predict that the innovations around these cell therapies will have as much impact on medicine as the silicon chip has had on technology.
What's something that most people just don't understand about your field?
There is a lot of confusion regarding the source of cells. When people hear "stem cells" they typically immediately relate that to mean "embryonic stem cells," or stem cells that are obtained by killing embryos. Yet, essentially all of the clinical work around the world is based on the adult stem cell. These are cells that we all have in our bodies (even a newborn has "adult stem cells"). We have them because they are involved in the continual cycle of tissue replacement and repair. It is these repair cells that are the most practical and accessible.
What's an emerging trend you think will shake up the health world?
Medical tourism is gaining momentum worldwide. As the world becomes more "flat," medicine becomes somewhat of a commodity. With ever-increasing access to information, patients are doing more research on their conditions, and instead of only having access to treatment at their local medical facility, their reach becomes global. So when new technology is developed and available in one country and not another, savvy patients with the means to access it are able to identify, research, and ultimately receive the care they might not have otherwise. This hopefully will drive down the cost of care, speed the access to innovations, and raise the standard of care globally.
What's a health trend that you wish would go away?
Heart disease is the leading killer in the Western world and has been for more than a century. It has been increasing in prevalence, now representing 17 percent of direct U.S. healthcare costs, and is projected to triple over the next two decades. Cell therapy has the potential to reverse this trend. In our European trial for patients experiencing large heart attacks, more than half the damage was reversed at the six month look compared to no change in the blinded standard of care control group. According to studies published in the literature, this should dramatically reduce the rate of patients progressing to heart failure, recurring heart attack, or death. For certain patients with heart failure who are no longer eligible for other therapies such as bypass surgery or stents, Cytori has completed a European trial demonstrating statistically significant improvement in key heart functional measures at both 6- and 18-month time points, again compared to blinded control patients who received the standard of care. Even though this was a relatively small study, the data is very strong. Based on these outcomes, we anticipate receiving European approval for this application this year.